MA56095A - Méthodes de traitement du cancer à l'aide d'inhibiteurs de prmt5 - Google Patents

Méthodes de traitement du cancer à l'aide d'inhibiteurs de prmt5

Info

Publication number
MA56095A
MA56095A MA056095A MA56095A MA56095A MA 56095 A MA56095 A MA 56095A MA 056095 A MA056095 A MA 056095A MA 56095 A MA56095 A MA 56095A MA 56095 A MA56095 A MA 56095A
Authority
MA
Morocco
Prior art keywords
cancer treatment
treatment methods
prmt5 inhibitors
prmt5
inhibitors
Prior art date
Application number
MA056095A
Other languages
English (en)
Inventor
Dirk Brehmer
Anthony T Greway
Yue Guo
Nahor Haddish-Berhane
Josh Lauring
Geert S J Mannens
Kathryn Elizabeth Packman
Hillary Joy Millar Quinn
Tongfei Wu
Hong Xie
Junguo Zhou
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA56095A publication Critical patent/MA56095A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA056095A 2019-06-06 2020-06-05 Méthodes de traitement du cancer à l'aide d'inhibiteurs de prmt5 MA56095A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858076P 2019-06-06 2019-06-06
EP19193850 2019-08-27

Publications (1)

Publication Number Publication Date
MA56095A true MA56095A (fr) 2022-04-13

Family

ID=70922068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056095A MA56095A (fr) 2019-06-06 2020-06-05 Méthodes de traitement du cancer à l'aide d'inhibiteurs de prmt5

Country Status (15)

Country Link
US (2) US11571437B2 (fr)
EP (1) EP3980019A1 (fr)
JP (1) JP2022535406A (fr)
KR (1) KR20220017989A (fr)
CN (1) CN113966232A (fr)
AU (1) AU2020286961A1 (fr)
BR (1) BR112021024469A2 (fr)
CA (1) CA3142825A1 (fr)
IL (1) IL288665A (fr)
JO (1) JOP20210320A1 (fr)
MA (1) MA56095A (fr)
MX (1) MX2021014944A (fr)
SG (1) SG11202112439YA (fr)
TW (1) TW202112375A (fr)
WO (1) WO2020245365A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153161A1 (fr) * 2021-01-14 2022-07-21 Pfizer Inc. Traitement du cancer à l'aide d'un inhibiteur de prmt5
CN115161341B (zh) * 2022-06-10 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用
WO2024118943A2 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt5

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003039523A2 (fr) 2001-11-05 2003-05-15 Exiqon A/S Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
US7144871B2 (en) 2002-02-19 2006-12-05 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US20060167241A1 (en) 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
WO2008001101A2 (fr) 2006-06-29 2008-01-03 Astex Therapeutics Limited Combinaisons pharmaceutiques
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
EP3587434A1 (fr) 2008-09-23 2020-01-01 Alnylam Pharmaceuticals Inc. Modifications chimiques de monomères et d'oligonucléotides avec des composants click capables de conjugaison de ligands
CA2784596A1 (fr) 2009-12-18 2011-06-23 Joslin Diabetes Center, Inc. Composes promouvant la replication des cellules beta et methodes d'utilisation de ces composes
CN103339139A (zh) 2010-12-03 2013-10-02 Epizyme股份有限公司 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法
EP2646455A4 (fr) 2010-12-03 2014-04-02 Epizyme Inc Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
WO2012083170A1 (fr) 2010-12-16 2012-06-21 Abbott Laboratories Composés antiviraux
EP2694524B1 (fr) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100730A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de la prmt5 contenant une dihydro- ou tétrahydro-isoquinoléine et leurs utilisations
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9856218B2 (en) * 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GEP20197047B (en) 2014-07-01 2019-12-10 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
KR20170119705A (ko) 2015-02-24 2017-10-27 화이자 인코포레이티드 항암제로서 유용한 치환된 뉴클레오시드 유도체
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CA3016096C (fr) 2016-03-10 2023-10-17 Janssen Pharmaceutica Nv Analogues de nucleosides substitues destines a etre utilises en tant qu'inhibiteurs de prmt5
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
TN2019000087A1 (en) 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
JOP20190199B1 (ar) 2017-02-27 2023-09-17 Janssen Pharmaceutica Nv استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5
BR112020010815A2 (pt) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos

Also Published As

Publication number Publication date
US20200384006A1 (en) 2020-12-10
WO2020245365A1 (fr) 2020-12-10
BR112021024469A2 (pt) 2022-01-18
CA3142825A1 (fr) 2020-12-10
MX2021014944A (es) 2022-01-24
IL288665A (en) 2022-02-01
KR20220017989A (ko) 2022-02-14
TW202112375A (zh) 2021-04-01
SG11202112439YA (en) 2021-12-30
JP2022535406A (ja) 2022-08-08
EP3980019A1 (fr) 2022-04-13
CN113966232A (zh) 2022-01-21
AU2020286961A1 (en) 2022-02-03
US20230241087A1 (en) 2023-08-03
JOP20210320A1 (ar) 2023-01-30
US11571437B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA45037A (fr) Polythérapie à base d'arnm pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA56095A (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de prmt5
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
IL279260A (en) KDM1A inhibitors for the treatment of diseases
MA48637A (fr) Polythérapies pour le traitement du cancer
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA54860A (fr) Méthodes de traitement du myélome multiple
MA54313A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
MA52627A (fr) Traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA52137A (fr) Méthodes de traitement de l'amylose ttr à l'aide d'ag10
MA52499A (fr) Associations pour le traitement du cancer